| volasertib (NBL-001) / Oncoheroes, Notable Labs |
NCT02273388: BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours |
|
|
| Completed | 1 | 65 | Europe | BI 6727 | Boehringer Ingelheim | Neoplasms | 01/09 | 04/21 | | |
NCT01145885: BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours |
|
|
| Completed | 1 | 7 | Europe | BI 6727 | Boehringer Ingelheim | Neoplasms | 11/10 | 11/10 | | |
NCT00969553: Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers |
|
|
| Completed | 1 | 59 | RoW | BI 6727 | Boehringer Ingelheim | Neoplasms | 09/11 | 09/11 | | |
NCT00969761: BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour |
|
|
| Completed | 1 | 61 | Europe | BI-6727, BI 6727 | Boehringer Ingelheim | Neoplasms | 11/11 | 02/12 | | |
|
NCT01348347: BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours |
|
|
| Completed | 1 | 15 | Japan | Volasertib, low dose, d1q3w, Volasertib, middle dose, d1q3w, Volasertib, high dose, d1q3w | Boehringer Ingelheim | Neoplasms | 08/12 | 05/14 | | |
|
NCT01206816: An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours |
|
|
| Completed | 1 | 57 | Europe | BI 6727 + BIBW 2992 | Boehringer Ingelheim | Neoplasms | 11/12 | 11/12 | | |
|
NCT01022853: Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors |
|
|
| Completed | 1 | 30 | Europe | BI 6727, BIBF 1120 | Boehringer Ingelheim | Neoplasms | 02/13 | 02/13 | | |
NCT01772563: Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours |
|
|
| Completed | 1 | 28 | Europe | volasertib, itraconazole, Orungal® | Boehringer Ingelheim | Neoplasms | 05/14 | 04/21 | | |
NCT02201329: Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
|
|
| Completed | 1 | 5 | Japan | Azacitidine, Volasertib | Boehringer Ingelheim | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | 01/15 | 09/15 | | |
NCT02003573: Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) |
|
|
| Terminated | 1 | 13 | US | decitabine iv, volasertib iv infusion | Boehringer Ingelheim | Leukemia, Myeloid, Acute | 01/15 | 05/16 | | |
NCT01662505: Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) |
|
|
| Completed | 1 | 19 | Japan | Volasertib | Boehringer Ingelheim | Leukemia, Myeloid, Acute | 05/15 | 05/15 | | |
NCT01971476 / 2013-001291-38: Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known |
|
|
| Completed | 1 | 22 | Europe, RoW | volasertib | Boehringer Ingelheim | Leukemia, Neoplasms | 06/15 | 01/17 | | |
NCT02721875: Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes |
|
|
| Terminated | 1 | 1 | Japan | Volasertib, Azacitidine | Boehringer Ingelheim | Myelodysplastic Syndromes | 06/16 | 07/16 | | |
NCT02757248: Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL |
|
|
| Withdrawn | 1 | 0 | US | Volasertib, Romidepsin | Anne Beaven, MD, National Comprehensive Cancer Network, Boehringer Ingelheim | PTCL, CTCL | 11/16 | 11/16 | | |
NCT01957644: Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML |
|
|
| Terminated | 1 | 16 | Europe | Azacitidine, Volasertib | Boehringer Ingelheim | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | 12/16 | 12/16 | | |
NCT02905994: Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia |
|
|
| Withdrawn | 1 | 0 | US | Volasertib, BI 6727, Cytarabine, Depocyt, Idarubicin, Idamycin, Bone Marrow Biopsy | Massachusetts General Hospital, Boehringer Ingelheim | AML | 02/17 | 02/17 | | |
NCT02875002: Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas |
|
|
| Withdrawn | 1 | 0 | US | volasertib, belinostat | Yale University, Massey Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Relapsed and Refractory Aggressive B- and T-cell Lymphomas, Lymphoma | 03/18 | 09/18 | | |
VIAC, NCT02527174: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia |
|
|
| Withdrawn | 1 | 0 | Canada | Volasertib, BI 6727, Idarubicin, Cytarabine, Ara-C | University of Alberta | Leukemia, Myeloid, Acute, Leukemia, Monocytic, Acute, Leukemia, Myelomonocytic, Acute, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute | 05/18 | 09/18 | | |
NCT02722135 / 2015-004625-14: A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed |
|
|
| Withdrawn | 1 | 0 | Europe | Volasertib | Boehringer Ingelheim | Leukemia, Myeloid, Acute | 05/18 | 09/18 | | |
NCT02861040: Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Withdrawn | 1 | 0 | US | Laboratory Biomarker Analysis, Pharmacological Study, Vincristine Sulfate Liposome, Marqibo, Volasertib, BI 6727, BI-6727, Polo-like Kinase 1 Inhibitor BI 6727 | Northwestern University, National Comprehensive Cancer Network, National Cancer Institute (NCI) | Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia | 07/18 | | | |
